GlassScriptPhysician profile
Robert Eisenband
NPI 1053301390
$9,333.19
in general payments reported to CMS, 2019-2025
41 companies · $1,393 in 2025
The $1,393 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,438 · 2020: $553 · 2021: $1,597 · 2022: $1,260 · 2023: $1,243 · 2024: $1,849 · 2025: $1,393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,447 · Education: $38.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,446.98 |
| Education | $38.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,952.52 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,124.87 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Celgene Corporation | $559.00 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $558.53 | 2019-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $436.66 | 2019-2025 | Entyvio, Takhzyro |
| Merck Sharp & Dohme LLC | $430.53 | 2019-2024 | Dificid, Zinplava |
| Lilly USA, LLC | $348.81 | 2024-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $308.68 | 2019-2025 | Ocaliva |
| Pfizer INC. | $266.41 | 2019-2025 | |
| Madrigal Pharmaceuticals | $238.76 | 2024-2025 | Rezdiffra, Resmetirom |
| Aimmune Therapeutics, INC. | $209.20 | 2023-2025 | Zenpep |
| Vivus LLC | $196.97 | 2021-2025 | Qsymia, Pancreaze |
| Allergan, INC. | $177.88 | 2019-2020 | |
| Celltrion USA INC. | $160.82 | 2024-2025 | Vegzelma, Zymfentra |
| Ipsen Biopharmaceuticals, INC | $158.60 | 2024-2025 | Iqirvo |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $131.19 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $92.37 | 2022 | |
| Ucb, INC. | $90.80 | 2019 | |
| Ferring Pharmaceuticals INC. | $84.82 | 2019-2023 | Rebyota |
| Nestle Healthcare Nutrition INC. | $84.68 | 2020-2023 | |
| Boston Scientific Corporation | $61.44 | 2021-2024 | |
| Gilead Sciences, INC. | $57.16 | 2020-2023 | |
| Daiichi Sankyo INC. | $53.59 | 2020-2022 | |
| Amgen INC. | $51.59 | 2023 | Amjevita, Avsola |
| Phathom Pharmaceuticals, INC. | $50.30 | 2024-2025 | Voquezna |
| Ambu INC. | $48.60 | 2020-2021 | |
| Redhill Biopharma INC. | $47.86 | 2020 | |
| Sandoz INC. | $43.74 | 2023-2024 | Hyrimoz |
| Ironwood Pharmaceuticals, INC | $41.38 | 2020-2021 | |
| Ardelyx, INC. | $41.04 | 2024 | Ibsrela |
| Romark Laboratories, Lc | $39.27 | 2019-2020 | |
| Medtronic, INC. | $32.00 | 2024 | Interstim |
| Novo Nordisk INC | $25.82 | 2025 | Wegovy |
| Otsuka America Pharmaceutical, INC. | $20.13 | 2019 | |
| Fresenius Kabi USA, LLC | $17.65 | 2023 | Idacio |
| Horizon Therapeutics Plc | $17.35 | 2020 | |
| Intra-Sana Laboratories | $16.09 | 2021-2022 | |
| Exact Sciences Corporation | $15.96 | 2023 | Cologuard Collection Kit |
| Lumendi LLC | $14.90 | 2021 | |
| Organon LLC | $13.81 | 2023 | Renflexis, Hadlima |
| Evoke Pharma, INC. | $11.41 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Eisenband listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.